Log in

NYSEAMERICAN:PFNXPfenex Stock Price, Forecast & News

-0.24 (-2.93 %)
(As of 07/13/2020 04:00 PM ET)
Today's Range
Now: $7.96
50-Day Range N/A
52-Week Range
Now: $7.96
Volume143,000 shs
Average Volume342,491 shs
Market Capitalization$272.39 million
P/E RatioN/A
Dividend YieldN/A
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
Read More
Pfenex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Previous SymbolNYSEMKT:PFNX



Sales & Book Value

Annual SalesN/A



Market Cap$272.39 million
Next Earnings Date8/13/2020 (Estimated)

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Pfenex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pfenex.

When is Pfenex's next earnings date?

Pfenex is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Pfenex.

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) issued its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.07. The biotechnology company earned $0.68 million during the quarter, compared to analysts' expectations of $3.75 million. View Pfenex's earnings history.

What price target have analysts set for PFNX?

5 equities research analysts have issued 1-year target prices for Pfenex's shares. Their forecasts range from $13.00 to $20.00. On average, they anticipate Pfenex's stock price to reach $16.75 in the next year. This suggests a possible upside of 110.4% from the stock's current price. View analysts' price targets for Pfenex.

Has Pfenex been receiving favorable news coverage?

Headlines about PFNX stock have trended very negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pfenex earned a daily sentiment score of -3.6 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Pfenex.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), Immunomedics (IMMU), Ocular Therapeutix (OCUL), Opko Health (OPK), Ring Energy (REI), Ring Energy (REI), TG Therapeutics (TGTX), Verastem (VSTM) and Bausch Health Companies (BHC).

Who are Pfenex's key executives?

Pfenex's management team includes the following people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $7.96.

How big of a company is Pfenex?

Pfenex has a market capitalization of $272.39 million. Pfenex employs 71 workers across the globe.

What is Pfenex's official website?

The official website for Pfenex is www.pfenex.com.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.